Healthcare -
Medical - Healthcare Information Services - NASDAQ - US
$ 3.35
27.4 %
$ 3.4 M
Market Cap
None
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Aclarion, Inc.
| Current Assets | 1.29 M |
| Cash & Short-Term Investments | 1.02 M |
| Receivables | 13.4 K |
| Other Current Assets | 255 K |
| Non-Current Assets | 1.17 M |
| Long-Term Investments | 0 |
| PP&E | 1.78 K |
| Other Non-Current Assets | 1.17 M |
| Current Liabilities | 3.19 M |
| Accounts Payable | 761 K |
| Short-Term Debt | 1.13 M |
| Other Current Liabilities | 1.3 M |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Aclarion, Inc.
| Revenue | 75.4 K |
| Cost Of Revenue | 75.7 K |
| Gross Profit | -324 |
| Operating Expenses | 4.88 M |
| Operating Income | -4.88 M |
| Other Expenses | 35.4 K |
| Net Income | -4.91 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Aclarion, Inc.
| Net Income | -4.91 M |
| Depreciation & Amortization | 163 K |
| Capital Expenditures | -120 K |
| Stock-Based Compensation | 456 K |
| Change in Working Capital | 623 K |
| Others | 427 K |
| Free Cash Flow | -3.77 M |
Wall Street Analysts Price Targets
Aclarion, Inc.
ACON has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
ACON does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Aclarion, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 years ago
Feb 16, 2023
|
Bought
1 K USD
|
Thramann Jeffrey John
Executive Chairman
|
+ 1
|
1000 USD |
|
2 years ago
Dec 29, 2022
|
Bought
4.47 K USD
|
Ness Brent
Chief Executive Officer
|
+ 7711
|
0.58 USD |
|
2 years ago
Dec 29, 2022
|
Bought
4.34 K USD
|
Ness Brent
Chief Executive Officer
|
+ 8500
|
0.51 USD |
|
2 years ago
Dec 28, 2022
|
Bought
961 USD
|
Ness Brent
Chief Executive Officer
|
+ 2289
|
0.42 USD |
|
2 years ago
Dec 29, 2022
|
Bought
8.24 K USD
|
Lorbiecki John Paul
Chief Financial Officer
|
+ 18304.441
|
0.45 USD |
|
2 years ago
Dec 29, 2022
|
Bought
1.76 K USD
|
Lorbiecki John Paul
Chief Financial Officer
|
+ 4100
|
0.43 USD |
|
2 years ago
Apr 22, 2022
|
Bought
15.3 K USD
|
Bond Ryan
Chief Strategy Officer
|
+ 21000
|
0.73 USD |
|
2 years ago
Apr 21, 2022
|
Bought
47.8 K USD
|
Wesemann William
director:
|
+ 11000
|
4.35 USD |
|
2 years ago
Apr 21, 2022
|
Bought
47.8 K USD
|
Wesemann William
Director
|
+ 11000
|
4.35 USD |
|
2 years ago
Apr 21, 2022
|
Bought
0 USD
|
Ness Brent
Chief Executive Officer
|
+ 1000
|
0 USD |
|
2 years ago
Apr 21, 2022
|
Bought
0 USD
|
Neal David K
director:
|
+ 34400
|
0 USD |
7. News
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit
Dr. Nicholas Theodore to highlight NOCISCAN capabilities combining MR Spectroscopy and augmented intelligence (AI) NOCISCAN is an innovative decision support tool that helps physicians personalize treatment for chronic low back pain BROOMFIELD, Colo., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the 2025 Spine Summit.
globenewswire.com
- 1 week ago
Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body
Recent Notice of Allowance is for Aclarion's 24th issued US patent Propionic acid (PA) is a biomarker the literature suggests may be indicative of bacterial infection and pain in an intervertebral disc Patent will expand Aclarion's proprietary rights to use MRS to measure propionic acid as a biomarker for the identification of potential infection and pain throughout the body BROOMFIELD, Colo., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its 24th issued US patent.
globenewswire.com
- 2 weeks ago
Aclarion Announces Northwestern Medicine as First CLARITY Trial Site
Northwestern Medicine is a global leader in clinical trial research, including spine CLARITY is a randomized study designed to demonstrate Nociscan's ability to improve surgical outcomes while reducing costs for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc.
globenewswire.com
- 3 weeks ago
Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded
The Company has secured nearly $20 million in gross proceeds in 2025 ensuring complete funding for its pivotal CLARITY trial CLARITY is a prospective, randomized, multicenter study to validate Nociscan's ability to improve surgical outcomes Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it has secured full funding for its pivotal CLARITY trial which is designed to demonstrate Nociscan's clinical and economic value in spine surgery.
globenewswire.com
- 3 weeks ago
Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded
Broomfield, CO, February 4, 2025 – PRISM MediaWire – Aclarion, Inc.
prismmediawire.com
- 3 weeks ago
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference
BROOMFIELD, Colo., January 31, 2025 – PRISM MediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the Selby Spine Conference.
prismmediawire.com
- 1 month ago
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference
Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI) NOCISCAN as New Gold Standard in Identifying a Source of Discogenic Pain BROOMFIELD, Colo., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the Selby Spine Conference.
globenewswire.com
- 1 month ago
Aclarion (ACON) Upgraded to Buy: Here's What You Should Know
Aclarion (ACON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 2 months ago
Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash
Article Focuses on how Leading Physicians are Incorporating Nociscan Into Their Clinical Practices for Chronic Low Back Pain Patients
globenewswire.com
- 3 months ago
Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st
BROOMFIELD, CO / ACCESSWIRE / November 14, 2024 / Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq:ACON)(Nasdaq:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its participation at the upcoming Virtual Investor Summit Microcap Event on November 21st. The Company will be available for 1-on-1 meetings throughout the day in addition to its formal presentation.
accesswire.com
- 3 months ago
Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit
Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024 BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Aclarion's CEO, Brent Ness, has been invited to present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, on Tuesday, October 15th, 2024, at 2:00 p.m.
globenewswire.com
- 4 months ago
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
Modic Changes (MC) are MRI Findings Associated With Endplate Damage, Neoinnervation, and Chronic Low Back Pain (cLBP) MR Spectroscopy (MRS) Measurement of Intradiscal Propionic Acid (PA) can Clarify MC Etiology and Help Stratify MC Patients to Potentially Inform Better Treatment Decisions for cLBP Patients Results Presented at the 50th International Society for the Study of the Lumbar Spine (ISSLS) Annual Meeting 2024 BROOMFIELD, CO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that the Nociscan solution was utilized to better understand Modic changes (MC) in patients suffering from chronic low back pain (cLBP).
globenewswire.com
- 5 months ago
8. Profile
Summary
Aclarion, Inc. ACON
COUNTRY
US
INDUSTRY
Medical - Healthcare Information Services
MARKET CAP
$ 3.4 M
Dividend Yield
0.00%
Description
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Contact
951 Mariners Island Boulevard, San Mateo, CA, 94404
https://www.aclarion.com
IPO
Date
April 22, 2022
Employees
4
Officers
Dr. Jeffrey John Thramann M.D.
Executive Chairman
Mr. John Lorbiecki
Chief Financial Officer
Mr. Brent Ness
Chief Executive Officer, President & Director
Mr. Ryan Bond
Chief Strategy Officer